Jason B. Daly - Mar 3, 2024 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role: SVP, Chief Legal Officer
Signature: /s/ Denis Butkovic, Attorney-in-Fact
Stock symbol: AMRX
Transactions as of: Mar 3, 2024
Transactions value $: -$98,624
Form type: 4
Date filed: 3/5/2024, 04:54 PM
Previous filing: Mar 7, 2023
Next filing: Nov 19, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMRX	Class A Common Stock	Options Exercise		+22.6K	+156.38%		37.1K	Mar 3, 2024	Direct	F1, F2
transaction	AMRX	Class A Common Stock	Tax liability	-$39.2K	-7.17K	-19.3%	$5.47	30K	Mar 3, 2024	Direct	F3
transaction	AMRX	Class A Common Stock	Options Exercise		+38.2K	+127.59%		68.2K	Mar 3, 2024	Direct	F1, F2
transaction	AMRX	Class A Common Stock	Tax liability	-$59.4K	-10.9K	-15.93%	$5.47	57.3K	Mar 3, 2024	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMRX	Restricted Stock Units	Options Exercise	$0	-22.6K	-33.33%	$0.00	45.3K	Mar 3, 2024	Class A Common Stock	22.6K		Direct	F2, F4
transaction	AMRX	Restricted Stock Units	Options Exercise	$0	-38.2K	-25%	$0.00	115K	Mar 3, 2024	Class A Common Stock	38.2K		Direct	F2, F5
transaction	AMRX	Restricted Stock Units	Award	$0	+144K		$0.00	144K	Mar 4, 2024	Class A Common Stock	144K		Direct	F2, F6
transaction	AMRX	Performance-Based Restricted Stock Units	Award	$0	+287K		$0.00	287K	Mar 4, 2024	Class A Common Stock	287K		Direct	F7, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3	Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4	On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F5	On March 3, 2023, the reporting person was granted 152,905 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F6	The restricted stock units vest in four equal annual installments beginning on March 4, 2025.
F7	Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F8	Represents a performance-based restricted stock unit grant of 143,519 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period.